LGND

#1394
Ligand Pharmaceuticals Inc.
231.2650 USD
+8.35%
セクター: ヘルスケア
ベース: USD
利益通貨: USD
日中レンジ
225.8000
231.4350
1年のレンジ
175.8900
231.4350
1日の変化
+8.35%
月次変化
+13.20%
6か月変化
+23.59%
1年の変化
+23.59%
以前の終値
213.4400
始値
230.0000
Bid
Ask
安値
225.8000
High
231.4350
ボリューム
91
チャート全体を表示

Financials

概要 明細書 統計 配当金
期次 年次
  • Market Capitalization 4.6117 B
  • Employee 47
  • Founded N/A
  • CEO N/A
  • Website www.ligand.com
  • Headquarter Delaware, United States
  • FIGI BBG000BKF014
  • Industry Technology
総売上高
当期純利益
1株当たり基本利益（基本EPS）
有利子負債合計
フリーキャッシュフロー
現金および現金同等物
株価収益率
30.84
売上高対価格比率
14.31
1株当たり配当金
2.5
配当利回り（％）
1.32

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol. The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments. Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020.

ニュース